Physician

Vikramsinh M. Dabhi, M.D.

According to 2025 Medicare claims, Vikramsinh Dabhi, M.D. (NPI: 1609923879) practices hematology/oncology in the Everett, WA market, with the plurality of this provider's patient population coming from Snohomish, WA. This provider's primary affiliated billing organization is PACMED CLINICS (NPI: 1477594356; TIN: 562290878) and primary practice location at 98021-4418. Dabhi is affiliated with the Health Connect Partners, LLC (ACO ID: A2342), participating under the MSSP model.

Dabhi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 159 traditional Medicare patients, billed 34,092 HCPCS/CPT codes, and received $543,319 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 570 prescription claims across 118 beneficiaries totaling $1,090,668 in drug costs, led by Imbruvica (Ibrutinib). 2022 DME data shows 41 claims. Open Payments data shows 3 records totaling $2,695. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $255,821 to $543,319. Similarly, Part D prescription costs have risen steadily, from $492,992 to $1,090,668. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	146	29,429	$255,821
2016	157	45,812	$406,998
2017	175	46,472	$355,420
2018	199	51,141	$1,002,409
2019	182	44,040	$799,408
2020	157	51,795	$723,446
2021	175	74,424	$1,258,461
2022	179	59,952	$1,380,877
2023	189	97,049	$901,321
2024	159	34,092	$543,319

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	75	634	$492,992
2016	72	537	$725,819
2017	73	553	$788,619
2018	83	561	$639,565
2019	85	593	$790,614
2020	87	699	$1,230,747
2021	103	694	$860,983
2022	112	676	$862,227
2023	127	822	$1,009,887
2024	118	570	$1,090,668

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	11	$207
2017	N/R	N/R	N/R
2018	N/R	50	$6,303
2019	N/R	N/R	N/R
2020	N/R	45	$6,618
2021	N/R	28	$1,771
2022	N/R	41	$2,286
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	26	36	$138
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	73	235	$102
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	34	40	$60
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	24	36	$46
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	91	167	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	13	364	$210,616
Eliquis	Apixaban	25	1,617	$32,574
Abiraterone Acetate	Abiraterone Acetate	17	570	$18,874
Xarelto	Rivaroxaban	12	900	$16,393
Anastrozole	Anastrozole	63	5,080	$876

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$2,695	Takeda Pharmaceuticals U.S.A., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vikramsinh M. Dabhi, M.D.?

Tedicare shows public-source Medicare data for Vikramsinh M. Dabhi, M.D. (NPI 1609923879), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vikramsinh M. Dabhi, M.D. have ACO affiliation data?

Vikramsinh M. Dabhi, M.D. is shown with ACO affiliation data for Health Connect Partners, LLC (MSSP, ACO ID A2342).

What billing organization is linked to Vikramsinh M. Dabhi, M.D.?

Vikramsinh M. Dabhi, M.D. is linked to PACMED CLINICS (billing NPI 1477594356) in the available physician profile data.

Does Vikramsinh M. Dabhi, M.D. have Open Payments data?

Vikramsinh M. Dabhi, M.D. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.